

# Bertrand Cariou

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3152324/bertrand-cariou-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

140  
papers

8,085  
citations

43  
h-index

88  
g-index

153  
ext. papers

9,596  
ext. citations

6.6  
avg, IF

5.9  
L-index

#	Paper	IF	Citations
140	Seipin localizes at endoplasmic-reticulum-mitochondria contact sites to control mitochondrial calcium import and metabolism in adipocytes.. <i>Cell Reports</i> , <b>2022</b> , 38, 110213	10.6	3
139	Plasma apolipoprotein concentrations and incident diabetes in subjects with prediabetes.. <i>Cardiovascular Diabetology</i> , <b>2022</b> , 21, 21	8.7	2
138	COVID-19 and Diabetes Outcomes: Rationale for and Updates from the CORONADO Study.. <i>Current Diabetes Reports</i> , <b>2022</b> , 22, 53	5.6	5
137	Impact of type 2 diabetes on the accuracy of non-invasive tests of liver fibrosis with resulting clinical implications.. <i>Clinical Gastroenterology and Hepatology</i> , <b>2022</b> ,	6.9	3
136	Generation of a GPR146 knockout human induced pluripotent stem cell line (ITXi001-A-1).. <i>Stem Cell Research</i> , <b>2022</b> , 60, 102721	1.6	0
135	Association of statin and/or renin-angiotensin-aldosterone system modulating therapy with mortality in adults with diabetes admitted to hospital with COVID-19: A retrospective multicentre European study.. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , <b>2022</b> , 16, 102484	8.9	0
134	A comment on metformin and COVID-19 with regard to "Metformin use is associated with a decrease in the risk of hospitalization and mortality in COVID-19 patients with diabetes: A population-based study in Lombardy".. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> ,	6.7	0
133	Protection by metformin against severe Covid-19: an in-depth mechanistic analysis. <i>Diabetes and Metabolism</i> , <b>2022</b> , 101359	5.4	1
132	PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs. <i>Stem Cell Reports</i> , <b>2021</b> ,	8	1
131	Phenotypic Differences Between Polygenic and Monogenic Hypobetalipoproteinemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2021</b> , 41, e63-e71	9.4	2
130	The association between metformin treatment and COVID-19 outcomes according to metformin continuation during hospitalisation. <i>Diabetes and Metabolism</i> , <b>2021</b> , 47, 101297	5.4	4
129	Influenza vaccination and prognosis for COVID-19 in hospitalized patients with diabetes: Results from the CORONADO study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> ,	6.7	1
128	La vie sans tissu adipeux: les lipodystrophies g�n�ralis�es cong�nitales; causes, physiopathologie et prise en charge th�rapeutique. <i>Medecine Des Maladies Metaboliques</i> , <b>2021</b> , 15, 157-170	0.1	
127	Impact of parathyroidectomy on cardiovascular risk in primary hyperparathyroidism: A narrative review. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2021</b> , 31, 981-996	4.5	3
126	La metformine est associ�e � une moindre mortalit�chez les patients diab�tiques hospitalis�s pour la COVID-19. <i>Medecine Des Maladies Metaboliques</i> , <b>2021</b> , 15, 278-287	0.1	
125	Phenotypic characteristics and prognosis of newly diagnosed diabetes in hospitalized patients with COVID-19: Results from the CORONADO study. <i>Diabetes Research and Clinical Practice</i> , <b>2021</b> , 175, 108695	7.4	9
124	Effects of proprotein convertase subtilisin kexin type 9 modulation in human pancreatic beta cells function. <i>Atherosclerosis</i> , <b>2021</b> , 326, 47-55	3.1	7

123	Anti-diabetic drugs and NASH: from current options to promising perspectives. <i>Expert Opinion on Investigational Drugs</i> , <b>2021</b> , 30, 813-825	5.9	2
122	The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia. <i>JACC: Cardiovascular Imaging</i> , <b>2021</b> , 14, 2414-2424	8.4	8
121	Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study. <i>Diabetes and Metabolism</i> , <b>2021</b> , 47, 101202	5.4	43
120	Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: Results from the CORONADO study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 391-403	6.7	35
119	Metformin use is associated with a reduced risk of mortality in patients with diabetes hospitalised for COVID-19. <i>Diabetes and Metabolism</i> , <b>2021</b> , 47, 101216	5.4	36
118	Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. <i>Diabetes and Vascular Disease Research</i> , <b>2021</b> , 18, 1479164121995928	3.3	1
117	Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study. <i>Diabetologia</i> , <b>2021</b> , 64, 778-794	10.3	61
116	Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1162-1172	6.7	19
115	Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1069-1083	6.7	28
114	Diabète et COVID-19: les leçons de CORONADO. <i>Medecine Des Maladies Metaboliques</i> , <b>2021</b> , 15, 15-23	0.1	1
113	Large-scale screening of lipase acid deficiency in at risk population. <i>Clinica Chimica Acta</i> , <b>2021</b> , 519, 64-69	6.2	1
112	Sex disparities in COVID-19 outcomes of inpatients with diabetes: insights from the CORONADO study. <i>European Journal of Endocrinology</i> , <b>2021</b> , 185, 299-311	6.5	4
111	History of bariatric surgery and COVID 19 outcomes in patients with type 2 diabetes: results from the CORONADO study. <i>Obesity</i> , <b>2021</b> ,	8	1
110	Management of diabetes mellitus in patients with cirrhosis: An overview and joint statement. <i>Diabetes and Metabolism</i> , <b>2021</b> , 47, 101272	5.4	5
109	Familial Hypercholesterolemia-Risk-Score: A New Score Predicting Cardiovascular Events and Cardiovascular Mortality in Familial Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2021</b> , 41, 2632-2640	9.4	6
108	A high-throughput mass spectrometry-based assay for large-scale profiling of circulating human apolipoproteins. <i>Journal of Lipid Research</i> , <b>2020</b> , 61, 1128-1139	6.3	11
107	Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. <i>Diabetologia</i> , <b>2020</b> , 63, 1500-1515	10.3	442
106	Improvement in arterial stiffness (pOpmère) after bariatric surgery. Results from a prospective study. <i>Annales D'Endocrinologie</i> , <b>2020</b> , 81, 44-50	1.7	5

105	Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. <i>Cardiovascular Diabetology</i> , <b>2020</b> , 19, 14	8.7	12
104	Association between sleep disturbances, fear of hypoglycemia and psychological well-being in adults with type 1 diabetes mellitus, data from cross-sectional VARDIA study. <i>Diabetes Research and Clinical Practice</i> , <b>2020</b> , 160, 107988	7.4	5
103	Circulating PCSK9 levels are not associated with the conversion to type 2 diabetes. <i>Atherosclerosis</i> , <b>2020</b> , 293, 49-56	3.1	9
102	Bile acids associate with glucose metabolism, but do not predict conversion from impaired fasting glucose to diabetes. <i>Metabolism: Clinical and Experimental</i> , <b>2020</b> , 103, 154042	12.7	9
101	Comment on Chen et al. Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication. <i>Diabetes Care</i> 2020;43:1399-1407. <i>Diabetes Care</i> , <b>2020</b> , 43, e163-e164	14.6	4
100	SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , <b>2020</b> , 306, 41-49	3.1	13
99	Circulating Rather Than Intestinal PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Regulates Postprandial Lipemia in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2020</b> , 40, 2084-2094	9.4	9
98	PCSK9 post-transcriptional regulation: Role of a 3'UTR microRNA-binding site variant in linkage disequilibrium with c.1420G. <i>Atherosclerosis</i> , <b>2020</b> , 314, 63-70	3.1	4
97	Phenotypic Characteristics and Development of a Hospitalization Prediction Risk Score for Outpatients with Diabetes and COVID-19: The DIABCOVID Study. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	10
96	Lipocalin-2 counteracts metabolic dysregulation in obesity and diabetes. <i>Journal of Experimental Medicine</i> , <b>2020</b> , 217,	16.6	17
95	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	26
94	Type 1 Diabetes in People Hospitalized for COVID-19: New Insights From the CORONADO Study. <i>Diabetes Care</i> , <b>2020</b> , 43, e174-e177	14.6	26
93	Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, Jñi P et al [letter]. <i>Diabetologia</i> , <b>2020</b> , 63, 2491-2494	10.3	4
92	Severely uncontrolled diabetes: a new aetiology of acquired bisalbuminaemia. <i>Diabetes and Metabolism</i> , <b>2020</b> , 46, 341-342	5.4	
91	Alirocumab efficacy and safety by body mass index: A pooled analysis from 10 Phase 3 ODYSSEY trials. <i>Diabetes and Metabolism</i> , <b>2020</b> , 46, 280-287	5.4	1
90	Fatty liver index is a strong predictor of changes in glycemic status in people with prediabetes: The IT-DIAB study. <i>PLoS ONE</i> , <b>2019</b> , 14, e0221524	3.7	16
89	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. <i>Diabetes Care</i> , <b>2019</b> , 42, 2262-2271	14.6	82
88	No association between fear of hypoglycemia and blood glucose variability in type 1 diabetes: The cross-sectional VARDIA study. <i>Journal of Diabetes and Its Complications</i> , <b>2019</b> , 33, 554-560	3.2	7

87	Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21 Suppl 1, 39-51	6.7	4
86	Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. <i>Diabetes Care</i> , <b>2019</b> , 42, 919-930	14.6	37
85	International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. <i>Diabetes Care</i> , <b>2019</b> , 42, 1147-1154	14.6	138
84	Sotagliflozin Added to Optimized Insulin Therapy Leads to Lower Rates of Clinically Relevant Hypoglycemic Events at Any HbA1c at 52 Weeks in Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , <b>2019</b> , 21, 471-477	8.1	9
83	Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicer cohort, and review of the literature. <i>Endocrine</i> , <b>2019</b> , 63, 348-360	4	18
82	Predicted Benign and Synonymous Variants in Cause Primary Adrenal Insufficiency Through Missplicing. <i>Journal of the Endocrine Society</i> , <b>2019</b> , 3, 201-221	0.4	13
81	Beyond LDL: What Role for PCSK9 in Triglyceride-Rich Lipoprotein Metabolism?. <i>Trends in Endocrinology and Metabolism</i> , <b>2018</b> , 29, 420-434	8.8	22
80	PCSK9 Concentrations in Cerebrospinal Fluid Are Not Specifically Increased in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 1519-1525	4.3	14
79	Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1479-1489	6.7	63
78	Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2018</b> , 38, 592-598	9.4	49
77	Inhibiting PCSK9 - biology beyond LDL control. <i>Nature Reviews Endocrinology</i> , <b>2018</b> , 15, 52-62	15.2	49
76	Prevalence of hypobetalipoproteinemia and related psychiatric characteristics in a psychiatric population: results from the retrospective HYPOPSY Study. <i>Lipids in Health and Disease</i> , <b>2018</b> , 17, 249	4.4	7
75	High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. <i>Atherosclerosis</i> , <b>2018</b> , 277, 334-340	3.1	18
74	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. <i>Diabetes Care</i> , <b>2018</b> , 41, 2552-2559	14.6	109
73	Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population. <i>Atherosclerosis</i> , <b>2018</b> , 278, 82-90	3.1	17
72	HbA and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study. <i>Diabetes Care</i> , <b>2018</b> , 41, 1981-1990	14.6	95
71	The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model. <i>Diabetes</i> , <b>2017</b> , 66, 1030-1040	0.9	84
70	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 97-105	18.1	225

69	Plasma PCSK9 concentrations during the course of nondiabetic chronic kidney disease: Relationship with glomerular filtration rate and lipid metabolism. <i>Journal of Clinical Lipidology</i> , <b>2017</b> , 11, 87-93	4.9	18
68	Post-term growth and cognitive development at 5 years of age in preterm children: Evidence from a prospective population-based cohort. <i>PLoS ONE</i> , <b>2017</b> , 12, e0174645	3.7	10
67	Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort. <i>Aids</i> , <b>2017</b> , 31, 2367-2376	3.5	14
66	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 864-876	18.1	174
65	Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1781-1792	6.7	84
64	Association Between Hypoglycemia and the Burden of Comorbidities in Hospitalized Vulnerable Older Diabetic Patients: A Cross-Sectional, Population-Based Study. <i>Diabetes Therapy</i> , <b>2017</b> , 8, 1405-1413	3.6	13
63	Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk. <i>Cardiovascular Diabetology</i> , <b>2017</b> , 16, 70	8.7	21
62	Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 448-451	6.7	12
61	E2F1 inhibits circulating cholesterol clearance by regulating Pcsk9 expression in the liver. <i>JCI Insight</i> , <b>2017</b> , 2,	9.9	27
60	Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. <i>Diabetes Care</i> , <b>2016</b> , 39, 1501-9	14.6	100
59	Efficacy of lixisenatide in patients with type 2 diabetes: A post hoc analysis of patients with diverse $\beta$ cell function in the GetGoal-M and GetGoal-S trials. <i>Journal of Diabetes and Its Complications</i> , <b>2016</b> , 30, 1385-92	3.2	13
58	Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. <i>DMM Disease Models and Mechanisms</i> , <b>2016</b> , 9, 81-90	4.1	30
57	Vitamin D deficiency is an independent risk factor for PTDM after kidney transplantation. <i>Transplant International</i> , <b>2016</b> , 29, 207-15	3	12
56	Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia. <i>Atherosclerosis</i> , <b>2016</b> , 250, 52-6	3.1	12
55	Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. <i>International Journal of Cardiology</i> , <b>2016</b> , 223, 750-757	3.2	48
54	No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. <i>European Heart Journal</i> , <b>2016</b> , 37, 2981-2989	9.5	108
53	From Human-Induced Pluripotent Stem Cells to Liver Disease Modeling: A Focus on Dyslipidemia. <i>Current Pathobiology Reports</i> , <b>2015</b> , 3, 47-56	2	2
52	Laparoscopic Gastric Banding in Obese Patients with Sleep Apnea: A 3-Year Controlled Study and Follow-up After 10 Years. <i>Obesity Surgery</i> , <b>2015</b> , 25, 1886-92	3.7	31



51	The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis. <i>Diabetologia</i> , <b>2015</b> , 58, 2051-5	10.3	36
50	Letter from Le May and Cariou regarding article, "Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms". <i>Circulation</i> , <b>2015</b> , 131, e427	16.7	
49	mTOR inhibitors and diabetes. <i>Diabetes Research and Clinical Practice</i> , <b>2015</b> , 110, 101-8	7.4	61
48	Patient and Physician Perspectives on Mode of Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels. <i>Clinical Therapeutics</i> , <b>2015</b> , 37, 1945-1954.e35	26.5	21
47	Long-term effects of Roux-en-Y gastric bypass on postprandial plasma lipid and bile acids kinetics in female non diabetic subjects: A cross-sectional pilot study. <i>Clinical Nutrition</i> , <b>2015</b> , 34, 911-7	5.9	40
46	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2015</b> , 385, 331-40	40	493
45	Role of PCSK9 beyond liver involvement. <i>Current Opinion in Lipidology</i> , <b>2015</b> , 26, 155-61	4.4	50
44	Sotagliflozin as a potential treatment for type 2 diabetes mellitus. <i>Expert Opinion on Investigational Drugs</i> , <b>2015</b> , 24, 1647-56	5.9	23
43	PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. <i>Atherosclerosis</i> , <b>2015</b> , 239, 252-9	3.1	32
42	Congenital lipodystrophies and dyslipidemias. <i>Current Atherosclerosis Reports</i> , <b>2014</b> , 16, 437	6	14
41	Preserved adrenal function in fully PCSK9-deficient subject. <i>International Journal of Cardiology</i> , <b>2014</b> , 176, 499-500	3.2	10
40	GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes. <i>Expert Opinion on Investigational Drugs</i> , <b>2014</b> , 23, 1441-8	5.9	20
39	The dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 exerts anti-diabetic effects in db/db mice without peroxisome proliferator-activated receptor gamma-associated adverse cardiac effects. <i>Diabetes and Vascular Disease Research</i> , <b>2014</b> , 11, 440-7	3.3	27
38	Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials. <i>BMC Cardiovascular Disorders</i> , <b>2014</b> , 14, 121	2.3	40
37	Function of seipin: new insights from Bslc2/seipin knockout mouse models. <i>Biochimie</i> , <b>2014</b> , 96, 166-72	4.6	22
36	Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Hepatology</i> , <b>2013</b> , 58, 1941-52	11.2	279
35	Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. <i>Nutrition and Metabolism</i> , <b>2013</b> , 10, 4	4.6	90
34	Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2013</b> , 33, 1484-93	9.4	125

33	Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2013</b> , 98, E732-6	5.6	27
32	Dual peroxisome proliferator-activated receptor $\alpha$ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. <i>Diabetes Care</i> , <b>2013</b> , 36, 2923-30	14.6	162
31	DPP-4 inhibitors in the treatment of type 2 diabetes. <i>Biochemical Pharmacology</i> , <b>2012</b> , 83, 823-32	6	66
30	New avenues for the pharmacological management of type 2 diabetes: an update. <i>Annales D'Endocrinologie</i> , <b>2012</b> , 73, 459-68	1.7	3
29	Thiazolidinediones and PPAR $\alpha$ agonists: time for a reassessment. <i>Trends in Endocrinology and Metabolism</i> , <b>2012</b> , 23, 205-15	8.8	283
28	Effects of the new dual PPAR $\alpha$ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism. <i>Diabetes Care</i> , <b>2011</b> , 34, 2008-14	14.6	140
27	Clinical aspects of PCSK9. <i>Atherosclerosis</i> , <b>2011</b> , 216, 258-65	3.1	120
26	Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. <i>Atherosclerosis</i> , <b>2011</b> , 219, 342-8	3.1	28
25	Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults. <i>Nutrition and Metabolism</i> , <b>2011</b> , 8, 48	4.6	74
24	TGR5 : un nouveau r�cepteur aux acides biliaires aux propri�t�s m�taboliques. <i>Medecine Des Maladies Metaboliques</i> , <b>2011</b> , 5, 37	0.1	1
23	Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. <i>Diabetes</i> , <b>2011</b> , 60, 1861-71	0.9	219
22	Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. <i>Atherosclerosis</i> , <b>2010</b> , 211, 700-2	3.1	42
21	Hypertriglycid�mie et n�phropathie chez le diab�tique de type 1: acteur ou marqueur ?. <i>Diabetologia Notes De Lecture</i> , <b>2010</b> , 2, 7-8		
20	High protein intake reduces intrahepatocellular lipid deposition in humans. <i>American Journal of Clinical Nutrition</i> , <b>2009</b> , 90, 1002-10	7	97
19	Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 684-90	9.4	133
18	PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2009</b> , 29, 2191-7	9.4	109
17	A corticotroph pituitary adenoma as the initial presentation of familial glucocorticoid deficiency. <i>European Journal of Endocrinology</i> , <b>2009</b> , 161, 195-9	6.5	5
16	L'invalidation s�lective de la lipase hormonosensible (HSL) dans la cellule b�pancr�tique chez la souris conduit � une hyperglyc�mie et � un blocage de l'oxocytose. <i>Diabetologia Notes De Lecture</i> , <b>2009</b> , 1, 15-16		



15	Le r�cepteur CD40 est exprim� dans l'adipocyte chez l'homme: implication dans le dialogue inflammatoire entre lymphocytes et adipocytes. <i>Diabetologia Notes De Lecture</i> , <b>2009</b> , 1, 27-28		
14	La chirurgie bariatrique amliore la fonction mitochondrial chez les ob�ses non diab�tiques seulement. <i>Diabetologia Notes De Lecture</i> , <b>2009</b> , 1, 65-66		
13	Role of bile acids and bile acid receptors in metabolic regulation. <i>Physiological Reviews</i> , <b>2009</b> , 89, 147-91	47.9	1093
12	PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion. <i>Biochemical and Biophysical Research Communications</i> , <b>2009</b> , 390, 1288-93	3.4	77
11	Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. <i>FEBS Letters</i> , <b>2008</b> , 582, 949-55	3.8	76
10	PCSK9 and LDL cholesterol: unravelling the target to design the bullet. <i>Trends in Biochemical Sciences</i> , <b>2008</b> , 33, 426-34	10.3	65
9	Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 9666-73	5.4	76
8	FXR: a promising target for the metabolic syndrome?. <i>Trends in Pharmacological Sciences</i> , <b>2007</b> , 28, 236-43	43.2	117
7	FXR-deficiency confers increased susceptibility to torpor. <i>FEBS Letters</i> , <b>2007</b> , 581, 5191-8	3.8	27
6	The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 11039-49	5.4	396
5	Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 6211-8	5.4	223
4	Potential regulatory role of the farnesoid X receptor in the metabolic syndrome. <i>Biochimie</i> , <b>2005</b> , 87, 93-8	4.6	29
3	Transient impairment of the adaptive response to fasting in FXR-deficient mice. <i>FEBS Letters</i> , <b>2005</b> , 579, 4076-80	3.8	69
2	The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. <i>Journal of Biological Chemistry</i> , <b>2005</b> , 280, 29971-9	5.4	169
1	Cellular and molecular mechanisms of adipose tissue plasticity in muscle insulin receptor knockout mice. <i>Endocrinology</i> , <b>2004</b> , 145, 1926-32	4.8	39